-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
NOD-, LRR- and pyridine domain-containing protein 3 (NLRP3) inflammasomes have been identified as important mediators of blood-brain barrier destruction in sepsis-related encephalopathy (SAE)
.
However, there is currently no information on key upstream regulators of SAE
.
Researchers used lipopolysaccharide (LPS) to establish an in vitro model of blood-brain barrier (BBB) destruction and an in vivo model of SAE
.
The destruction of BBB integrity was assessed by measuring the expression level of tight junction proteins
.
The results showed that Maf1 significantly inhibited LPS-induced brain inflammation and nerve apoptosis in vivo and in vitro
.
It is worth noting that Maf1 reduced the activation of NLRP3 inflammasome and the expression of pro-inflammatory cytokines induced by NF-κB/p65
.
In summary, the results of this study indicate that regulating Maf1 may be a treatment strategy for SAE and other inflammation-related neurodegenerative diseases
Original source:
Shenglong Chen, et al.
Maf1 Ameliorates Sepsis-Associated Encephalopathy by Suppressing the NF- k B / NLRP3 Inflammasome Signaling Pathway In this message